Michiel S. Van Der Heijden

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 154 publications

Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.

Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.

Journal: European urology

Published: May 05, 2026

DR. INFO at the Point of Care: A Prospective Pilot Study of Physician-Perceived Value of an Agentic Artificial Intelligence Clinical Assistant.

DR. INFO at the Point of Care: A Prospective Pilot Study of Physician-Perceived Value of an Agentic Artificial Intelligence Clinical Assistant.

Journal: Cureus

Published: April 21, 2026

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.

Journal: Future oncology (London, England)

Published: April 02, 2026

Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

Journal: Nature communications

Published: January 19, 2026

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

Journal: Nature medicine

Published: January 12, 2026

From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer.

From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer.

Journal: Nature reviews. Clinical oncology

Published: December 16, 2025

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.

Journal: ESMO open

Published: October 31, 2025

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials.

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials.

Journal: European urology oncology

Published: October 21, 2025

PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.

PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.

Journal: The Journal of urology

Published: October 09, 2025

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.

Journal: International journal of clinical oncology

Published: September 16, 2025

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Journal: CA: a cancer journal for clinicians

Published: September 15, 2025

Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 09, 2025

Showing 1-12 of 154

Last Updated: 09/26/2026